We wondered whether these differences in GAF degradation abilities between cell types could be linked to different gene expression known to segregate between resting and activated fibroblasts or even myofibroblastic cells like cancer-associated fibroblasts (CAFs), all being known to have quite distinct ECM-degradation abilities. This evidence concerns the gene FGF9 and cancer.